Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Sickle Cell Program at UI HealthThe Sickle Cell Program at UI Health is ...
-
Opioid management strategy decreases admissions in high-utilizing adults with sickle cell diseaseBackground: A subset of adults with sic...
-
My medical school lesson was tinged with racism. Did that affect how I treated a sickle cell patient years later?The young woman was curled up in a ball....
-
Thomas Coates, MDDr. Thomas is currently working as secti...
-
High mortality among children with sickle cell anemia and overt stroke who discontinue blood transfusion after trans...BACKGROUND: Chronic blood transfusion is...
-
Children’s of AlabamaPediatric Hematology specialists at the ...
-
Martin H. Steinberg, MDDr. Steinberg is currently working as pr...
